Navigation Links
Piedmont Pharmaceuticals Secures $8.5 Million Investment
Date:11/12/2007

GREENSBORO, N.C., Nov. 12 /PRNewswire/ -- Piedmont Pharmaceuticals LLC, a specialty pharmaceutical company focused on parasitology and drug delivery systems for human and companion animal use, has secured $8.5 million in Series B financing from CM Capital Investments of Brisbane, Australia, and other accredited investors.

This funding will help advance development of Piedmont Pharmaceuticals' pipeline, particularly the U.S. Phase III clinical trials of its unique patented, insecticide-free head lice treatment. Through licensees abroad, this pediculicide rinse is already approved and is the market leader in the United Kingdom and Ireland (under the name Full Marks Solution(R)) and gaining market share in Canada (as RESULTZ(R)). While no timetable has been set, Piedmont Pharmaceuticals anticipates expanding distribution of the product through licensees in the European, Asian and Australasian markets.

"We are very pleased to be working with an investment company of CM Capital's geographical scope and expertise," said Roland Johnson, CEO and Chairman of the Board for Piedmont Pharmaceuticals. "We believe this investment, the first major institutional backing for Piedmont Pharmaceuticals, sends a strong signal about our company's progress and potential. As we move our pediculicide compound through Phase III trials and continue developing the rest of our portfolio, we welcome the guidance and global connections that CM Capital can offer."

"CM Capital invests in companies that can achieve market leadership positions in their respective market sectors," said Andy Jane, partner at CM Capital Investments. "With its talented and proven team of industry veterans, Piedmont Pharmaceuticals has an excellent opportunity to succeed in both the human and animal health markets in the U.S. and beyond."

Members of Piedmont Pharmaceuticals' team have worked together in the health care industry for more than 20 years, bringing more than 11 products to market. In addition to the pediculicide rinse, Piedmont Pharmaceuticals' pipeline includes a topical treatment for otitis media in humans and a chewable drug delivery platform for companion animals, both in preclinical stages.

About Piedmont Pharmaceuticals:

Piedmont Pharmaceuticals LLC is a Greensboro, N.C. - based specialty pharmaceutical company focused on human and animal health therapeutics in such select areas as parasitology and the treatment of infection. The company's currently commercialized products and advanced development program leverage unique modes of action and proprietary delivery technologies. Piedmont Pharmaceuticals develops new formulations, uses and delivery vehicles for known active pharmaceutical compounds for human and companion animal health markets.

About CM Capital Investments:

CM Capital is headquartered in Brisbane, Australia and is one of the pioneers of the Australian Venture Capital industry. They have over $270m under management and are one of Australia's leading early stage VC fund managers. Their investor base consists of some of Australia's leading superannuation funds and financial institutions. CM Capital is staffed by industry professionals with strong operational expertise and focuses its investments in the areas of life sciences, biotechnology and telecommunications/IT.

Note: Full Marks Solution(R) is a registered trademark of SSL International PLC, a licensee of Piedmont Pharmaceuticals.


'/>"/>
SOURCE Piedmont Pharmaceuticals LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... American ... chief medical officer of Blue Horizon International (BHI), Brian Mehling, M.D., spoke at ... held during May 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... and products recently hosted the first PowerWave Instructor Certification Course in Stoughton, Massachusetts. ... a group of fitness professional through the 8 hour interactive course to qualify ...
(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during ... Water Life Science® and international water advocate, was honored by Ashram, Inc. as the ... ancient Egypt who knelt on the banks of the Nile to fill their red ...
(Date:5/26/2016)... ... May 26, 2016 , ... Workrite ... sales leadership and to further develop their rapidly expanding portfolio of customer and ... with a concentration in Marketing and an M.B.A. with concentration in management from ...
(Date:5/26/2016)... ... , ... May 2016 – Lips may be a central feature on our ... numbers of clients now ask about lip plumping and primping techniques and want tips ... Advanced Dermatology P.C. , The trend is a national one, with 2.4 ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... CHESTERFIELD, Va. , May 25, 2016 /PRNewswire/ ... next-generation sequencing test for wounds and infections. This ... ALL parasites, and select viruses. The test requires ... area. David G. Bostwick ... molecular testing to facilitate wound healing: "We are ...
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
(Date:5/24/2016)...   , Study met ... bowel cleansing and superiority in , ... of the ascending colon   ... Norgine B.V. today announced new positive data from the phase ... preparation) versus standard 2 litre PEG with ascorbate. The study met ...
Breaking Medicine Technology: